2616 — CStone Pharmaceuticals Share Price
Last trade - 00:00- HK$1.09bn
- HK$374.00m
- CNY463.84m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.21 | ||
| Price to Tang. Book | 3.56 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.18 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -43.79% | ||
| Return on Equity | -81.05% | ||
| Operating Margin | -76.62% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | n/a | 1,038.83 | 243.72 | 481.36 | 463.84 | 661.97 | 701.65 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CStone Pharmaceuticals is a China-based investment holding company. Through its subsidiaries, the Company is primarily engaged in development, manufacturing and sales of biopharmaceutical products. Its main products include immuno-oncology drugs and molecularly targeted drugs. The Company conducts its businesses mainly in domestic market.
Directors
- Frank Jiang CHM (58)
- Richard Yeh CFO (52)
- Xinzhong Wang SVP (55)
- Jingrong Li SVP (58)
- Ngai Chiu Tse SVP (52)
- Jianxin Yang SVP (55)
- Bing Yuan SVP (49)
- Ning He SEC
- Jeanie Lau SEC
- Yanling Cao NED (37)
- Lian Yong Chen NED (58)
- Kenneth Hitchner NED (61)
- Edward Hu NED (58)
- Wei Li NED (49)
- Xianghong Lin NED (50)
- Paul Chew NID (66)
- Hongbin Sun NID (46)
- Ting Yuk Wu NID (67)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 2nd, 2015
- Public Since
- February 26th, 2019
- No. of Employees
- 230
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 1,284,191,212
- Address
- 1000 Zhangheng Road Bldg 25, SUZHOU, 200072
- Web
- https://www.cstonepharma.com/
- Phone
- +86 51287186550
- Auditors
- Deloitte Touche Tohmatsu
Latest News for 2616
Upcoming Events for 2616
CStone Pharmaceuticals Annual Shareholders Meeting
Half Year 2024 CStone Pharmaceuticals Earnings Release
Similar to 2616
Abbisko Cayman
Stock Exchange of Hong Kong Limited
Akeso
Stock Exchange of Hong Kong Limited
Alphamab Oncology
Stock Exchange of Hong Kong Limited
Antengene
Stock Exchange of Hong Kong Limited
Ascentage Pharma International
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 19:06 UTC, shares in CStone Pharmaceuticals are trading at HK$0.85. This share price information is delayed by 15 minutes.
Shares in CStone Pharmaceuticals last closed at HK$0.85 and the price had moved by -75.92% over the past 365 days. In terms of relative price strength the CStone Pharmaceuticals share price has underperformed the FTSE Developed Asia Pacific Index by -74.87% over the past year.
The overall consensus recommendation for CStone Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
CStone Pharmaceuticals does not currently pay a dividend.
CStone Pharmaceuticals does not currently pay a dividend.
CStone Pharmaceuticals does not currently pay a dividend.
To buy shares in CStone Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$0.85, shares in CStone Pharmaceuticals had a market capitalisation of HK$1.09bn.
Here are the trading details for CStone Pharmaceuticals:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 2616
Based on an overall assessment of its quality, value and momentum CStone Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in CStone Pharmaceuticals is HK$5.44. That is 540.41% above the last closing price of HK$0.85.
Analysts covering CStone Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -CNY0.19 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CStone Pharmaceuticals. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -57.18%.
As of the last closing price of HK$0.85, shares in CStone Pharmaceuticals were trading -55.89% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The CStone Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$0.85.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
CStone Pharmaceuticals' management team is headed by:
- Frank Jiang - CHM
- Richard Yeh - CFO
- Xinzhong Wang - SVP
- Jingrong Li - SVP
- Ngai Chiu Tse - SVP
- Jianxin Yang - SVP
- Bing Yuan - SVP
- Ning He - SEC
- Jeanie Lau - SEC
- Yanling Cao - NED
- Lian Yong Chen - NED
- Kenneth Hitchner - NED
- Edward Hu - NED
- Wei Li - NED
- Xianghong Lin - NED
- Paul Chew - NID
- Hongbin Sun - NID
- Ting Yuk Wu - NID